News >

Expert Discusses Latest CAR T-Cell Developments in Non-Hodgkin Lymphoma

Jason Harris
Published: Tuesday, Sep 04, 2018

David Maloney, MD, PhD

David Maloney, MD, PhD
Results in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) suggest that chimeric antigen receptor (CAR) T-cell therapy should be used earlier in treatment, possibly after first relapse, said David G. Maloney, MD, PhD. Administration of these products in earlier lines of therapy could improve outcomes and reduce toxicity, he added.

, Maloney reviewed the latest developments with CAR T-cell therapy in patients with NHL.

OncLive: What is the current state of treatment for DLBCL?

Maloney: DLBCL is a disease where we obviously try to cure it with chemotherapy and that can be remarkably successful in 60% to 70% of patients, but for those who don't go into complete remission or who relapse, then this becomes a life-threatening problem. Standard of care is salvage chemotherapy and, if you have responsive disease, autologous stem cell transplant. Unfortunately, with better therapies including R-CHOP, as the CORAL study showed, our success with transplant has gotten even lower. Therefore, people are very interested in the targeted therapies.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication
x